
Alumis Inc (ALMS) Stock Forecast & Price Target
Alumis Inc (ALMS) Analyst Ratings
Bulls say
Alumis Inc. presents a positive outlook due to its promising pipeline, particularly with ESK-001, which has demonstrated significant efficacy and safety data in treating moderate to severe plaque psoriasis, showing substantial improvements in patient-reported outcomes. The company is also increasing its terminal growth rate from 2% to 3%, reflecting a historical trend in expanded drug utility over time, which could positively impact long-term revenue prospects. Additionally, Alumis' lead candidate, envudeucitinib, aims to attain superior efficacy and safety in multiple autoimmune indications, underscoring the company's potential to address substantial unmet medical needs in a growing market.
Bears say
Alumis Inc faces significant regulatory risks that could adversely affect its financial projections, as the success of its clinical trials does not guarantee product approval, which is critical for achieving revenue. The company also contends with competition from established products, highlighted by a recent decline in efficacy metrics, indicating potential challenges in differentiating its therapies from others in the market. Furthermore, logistical challenges, such as the administration requirements for icotrokinra, add to concerns regarding patient compliance, which could impact market adoption and overall commercial success.
This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.
Alumis Inc (ALMS) Analyst Forecast & Price Prediction
Start investing in Alumis Inc (ALMS)
Order type
Buy in
Order amount
Est. shares
0 shares